Parathyroid Hormone Predicts Fracture, Vascular Events, Death in CKD
In a study of CKD patients, patients with baseline PTH levels of 0, 69, and 58 pg/mL had the lowest risks for fracture, vascular events, and death, respectively.
Secondary Hyperparathyroidism
Preoperative Potassium Predicts Hyperkalemia Post-Parathyroidectomy
In a study of hemodialysis patients, pre-operative potassium higher than 3.9 mmol/L correlated with greater risk for hyperkalemia after parathyroidectomy.
Vertebral Fracture Common in ESRD
In a small study, 34% of dialysis patients had vertebral fractures, and patients in the highest tertile of parathyroid hormone level had a nearly 3-fold increased risk of these fractures compared with those in the middle tertile.
Higher Vitamin D Target May Be Needed to Manage SHPT
New data support aggressive vitamin D repletion to a revised serum 25-hydroxyvitamin D target of at least 51 ng/mL in patients with chronic kidney disease.
Pre-Transplant Cinacalcet May Increase the Risk of Persistent SHPT
Twice as many patients taking a high cinacalcet dose before transplantation required subsequent parathyroidectomy persistent secondary hyperparathyroidism.
Cinacalcet Frequently Discontinued, Reinitiated
A European study of hemodialysis patients who were new users of cinacalcet found that the drug was discontinued in 35% of patients after 1 year.
Parathyroidectomy Ups Cardiovascular Risks in Dialysis Patients
Dialysis patients who underwent parathyroidectomy had a 24% greater risk for cardio- and cerebrovascular events than similar patients who did not undergo the surgery.
Study: Etelcalcetide Can Be Used Safely by Registered Dietitians, Nurses
In a study, hypocalcemia and gastrointestinal adverse events were managed through etelcalcetide dose modification or discontinuation.
Vitamin D and iPTH Levels Vary by Season
In a large study of dialysis patients, serum 25-hydroxyvitamin D levels peaked in summer and declined in winter.
Oral Evocalcet Appears Effective for SHPT
In 2 small trials of Japanese patients with SHPT on dialysis, evocalcet treatment reduced iPTH to target levels in a majority of patients within 30 to 32 weeks.
Next post in Secondary Hyperparathyroidism
